ViaDerma Finalizes Distribution Agreements in Dubai and Announces Six New Key Hires
Rhea-AI Summary
ViaDerma, Inc. (OTC Pink: VDRM) has announced significant developments in its global expansion strategy. The company has finalized distribution agreements with two leading companies in Dubai, aimed at expanding the availability of its flagship topical antibiotic product, Vitastem, in the Middle East and Eastern Europe. To support this growth, ViaDerma has made six key hires, including a Business Development Analyst, Project Manager, HR Specialist, Fractional COO, and a Regulatory Specialist with FDA experience. A new Chief Technology Officer is also set to join soon.
Dr. Christopher Otiko, President of ViaDerma, expressed optimism about the company's future growth prospects and hinted at a forthcoming announcement regarding a large international shipment of Vitastem. These strategic moves position ViaDerma for significant expansion beyond the United States market.
Positive
- Finalized distribution agreements in Dubai to expand market presence in Middle East and Eastern Europe
- Added six new key hires to support global expansion efforts
- Upcoming announcement of a large new international shipment of Vitastem
Negative
- None.
LOS ANGELES, Aug. 01, 2024 (GLOBE NEWSWIRE) -- ViaDerma, Inc. (OTC Pink: VDRM), a leader in innovative wound care solutions, proudly announces the successful completion of pivotal distribution agreements across the Middle East and Eastern Europe. Dr. Christopher Otiko, President of ViaDerma, recently returned from the United Arab Emirates, where he met with representatives from two leading distribution companies in Dubai and finalized agreements centered around ViaDerma's flagship topical antibiotic product. These agreements are designed to significantly expand the company's global market presence. The partner companies, known for their expertise in supplying wholesale products to private enterprises and government entities, will play a crucial role in enhancing the availability of Vitastem in these strategically important regions. This collaboration marks a major step forward in ViaDerma's mission to provide advanced wound care solutions globally.
As a result of these important partnerships, ViaDerma has added six new key hires to help coordinate the global expansion efforts. A Business Development Analyst, a Project Manager, an HR Specialist, a Fractional COO, and a Regulatory Specialist with 16 years of FDA experience began their new roles on June 1st. The company is also set to welcome a new Chief Technology Officer next week, who will play a crucial role in advancing the company's technological capabilities. These strategic hires underscore ViaDerma's commitment to expanding its expertise and operational capacity, enabling it to better serve its future global customer base.
“We are very pleased to enter into these new partnerships at this time and to welcome these talented individuals to our team,” said Dr. Otiko. “There have been many challenges to reach this point, but we feel we have finally positioned ourselves for significant growth outside of the United States. I believe we have set the stage for an exciting future as we work towards expanding the availability of Vitastem and other products we hope to roll out in the future.”
Dr. Otiko also said, “We expect to make an announcement as early as next week with details of a large new international shipment of Vitastem.”
About ViaDerma, Inc.
ViaDerma, Inc. (OTC: VDRM) is a publicly traded specialty pharmaceutical company committed to bringing new products to market and licensing its innovative transdermal drug delivery technology solutions to current leaders in the pharmaceutical industry in a wide variety of therapeutic areas. For more information, please visit: https://viaderma.com
Any forecast of future performance is a "forward looking statement" under securities laws. Such statements are included to allow potential investors the opportunity to understand management’s beliefs and opinions with respect to the future so that they may use such beliefs and opinions as one factor among many in evaluating an investment.
Contact information:
Investor Relations
Email: ir@viaderma.com
Phone: 310-734-6111
Follow ViaDerma on Twitter: https://twitter.com/viaderma
FAQ
What new distribution agreements has ViaDerma (VDRM) recently finalized?
How many new hires did ViaDerma (VDRM) announce in August 2024?
What is the main product ViaDerma (VDRM) is focusing on for international expansion?
When did the new hires at ViaDerma (VDRM) start their roles?
